BOUNDLESS: AN ACTIVE-CONTROLLED, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY TRIAL OF CONTINUOUS SUBCUTANEOUS INFUSION OF LEVODOPA/CARBIDOPA WITH ND0612 IN PATIENTS WITH PARKINSON'S DISEASE

被引：0
|
作者：
Rascol, O. [1 ,2 ]
Poewe, W. [3 ]
Stocchi, F. [4 ]
Yardeni, T. [5 ]
Barak, S. Leibman [5 ]
Adar, L. [5 ]
Rosenfeld, O. [5 ]
Olanow, C. W. [6 ]
机构：
[1] Univ Toulouse, CHU Toulouse, Toulouse, France
[2] INSERM, Toulouse, France
[3] Med Univ Innsbruck, Innsbruck, Austria
[4] IRCCS San Raffaele Pisana, Inst Neurol, Rome, Italy
[5] NeuroDerm Ltd, Rehovot, Israel
[6] Clintrex, Sarasota, FL USA
来源：
PARKINSONISM & RELATED DISORDERS | 2020年 / 79卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A 186
引用
收藏
页码：E53 / E53
页数：1
相关论文
共 50 条
  • [31] Subcutaneous foslevodopa/foscarbidopa in patients with advanced Parkinson's Disease: results from a randomized, double-blind, double-dummy phase 3 trial
    Soileau, M.
    Spindler, M.
    Aldred, J.
    Budur, K.
    Fisseha, N.
    Fung, V.
    Jeong, A.
    Kimber, T.
    Klos, K.
    Litvan, I.
    O'Neill, D.
    Robieson, W.
    Standaert, D.
    Talapala, S.
    Vaou, E. Okeanis
    Zheng, H.
    Facheris, M.
    Hauser, R.
    MOVEMENT DISORDERS, 2022, 37 : S354 - S354
  • [32] The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: A randomized, double-blind, active-controlled, double-dummy trial
    Kushida, K
    Shiraki, M
    Nakamura, T
    Kishimoto, H
    Morii, H
    Yamamoto, K
    Kaneda, K
    Fukunaga, M
    Inoue, T
    Nakashima, M
    Orimo, H
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (09): : 606 - 620
  • [33] Randomized, Double-Blind, Double-Dummy Study of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson's Disease: Functional and Quality-of-Life Outcomes
    Kieburtz, K.
    Antonini, A.
    Olanow, C. W.
    Fernandez, H. H.
    Espay, A. J.
    Standaert, D. G.
    Hass, S.
    Widnell, K. L.
    Robieson, W. Z.
    Pritchett, Y.
    Chatamra, K.
    Benesh, J.
    ANNALS OF NEUROLOGY, 2012, 72 : S99 - S99
  • [34] A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients
    Kirstin Stricker
    Sue Yu
    Gerhard Krammer
    BMC Musculoskeletal Disorders, 9
  • [35] A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients
    Stricker, Kirstin
    Yu, Sue
    Krammer, Gerhard
    BMC MUSCULOSKELETAL DISORDERS, 2008, 9 (1)
  • [36] Design of a randomized, double-blind, double-dummy, placebo-controlled study of levodopa-carbidopa intestinal gel in patients currently receiving optimized treatment for advanced Parkinson's disease
    Olanow, C. W.
    Chatamra, K.
    Benesh, J.
    Pritchett, Y. L.
    Lenz, R. A.
    MOVEMENT DISORDERS, 2011, 26 : S137 - S137
  • [37] Randomized, double-blind, double-dummy, controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease
    Herrlinger, K
    Witthoeft, T
    Raedler, A
    Bokemeyer, B
    Krummenerl, T
    Schulzke, J
    Boerner, N
    Kueppers, B
    Emmrich, J
    Mescheder, A
    Schwertschlag, U
    Shapiro, M
    Stange, E
    GASTROENTEROLOGY, 2004, 126 (04) : A466 - A466
  • [38] ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson's disease achieves stable levodopa plasma levels when administered in low and high doses
    Giladi, Nir
    Caraco, Yoseph
    Gurevich, Tanya
    Djaldetti, Ruth
    Adar, Liat
    Cohen, Yael
    Minei, Tamar Rachmilewitz
    Oren, Sheila
    NEUROLOGY, 2017, 88
  • [39] Long-Term Efficacy of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) for Motor Fluctuations in Parkinson's disease (PD)
    Espay, A.
    Pahwa, R.
    Ellenbogen, A.
    Stocchi, F.
    Giladi, N.
    Salin, L.
    Sasson, N.
    Pereira, J.
    Rascol, O.
    MOVEMENT DISORDERS, 2024, 39 : S301 - S301
  • [40] A randomized, double-blind, double-dummy, placebo- and ropinirole-controlled trial of rotigotine in patients with advanced Parkinson's disease in Japan
    Mizuno, Y.
    Kondo, T.
    Hasegawa, K.
    Murata, M.
    Hattori, N.
    Nomoto, M.
    MOVEMENT DISORDERS, 2011, 26 : S136 - S136
12345